Why Are Investors Passing on Teva Pharmaceutical Industries?

Why Are Investors Passing on Teva Pharmaceutical Industries?

Source: 
Yahoo/Motley Fool
snippet: 

Teva Pharmaceutial Industries (NYSE: TEVA) is a dirt-cheap pharma stock. The company's shares are trading at a rock-bottom price-to-sales ratio of 0.88. That's a cut-rate valuation for any large cap pharma play, especially for one with a well-established global footprint like Teva. Nevertheless, this deeply discounted drugmaker has still failed to attract bargain hunters this year.